Coya Therapeutics announced that Arun Swaminathan has been promoted to the role of CEO effective November 1. He will succeed Howard Berman who will continue to serve in the capacity of executive chair. Coya also believes it will benefit from Swaminathan’s leadership in advancing COYA 302 in related programs such as Frontotemporal Dementia, Parkinson’s Disease and other immune mediated diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA: